Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Financial Officer, Thomas J. Russo, CFA on October 28, 2019.

Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo brings 25 years of experience in the biotechnology and pharmaceutical industry, spanning finance and operations (including commercial planning and manufacturing), as well as equity research.

Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer

CymaBay Therapeutics

Madrigal Pharmaceuticals

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

3 Things to Watch From the Pharmaceutical Industry's Liver Meeting

Investors digesting a late-breaking data drop pushed up the stock.

Here's Why Assembly Biosciences Jumped Again on Thursday

Shares of Assembly Biosciences rocketed in higher-than-average volume for a second day Thursday on excitement surrounding the biotech company's potential hepatitis B treatment.

This Biotech Stock Doubled In Two Days On Potential Hepatitis Cure

The company reported promising updates for two important pipeline programs.

Here's Why Assembly Biosciences Stock Soared Today

SOUTH SAN FRANCISCO, Calif., Oct.  16, 2019  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that data on its lead HBV core inhibitor candidates, ABI-H0731 (731) and ABI-H2158 (2158) for the treatment of chronic HBV will be featured in a late-breaking poster session during the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), November 8-12, 2019, in Boston.

Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLD

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

Mid-stage clinical trial results weren't what some investors were looking for.

Here's Why Assembly Biosciences Is Slipping Today

FibroGen

GW Pharmaceuticals

Heron Therapeutics

April's about to shower biopharma investors with important updates that could move these stocks.

Biotech Stocks With Major Catalysts in April

News for Assembly Biosciences Stock (ASMB)